SCHEMBL3569620

SCHEMBL3569620

CN(C)NN=C1C=CC(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2ccccc2F)=C(F)C1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.34
UTS2R Q9UKP6 4/20 0.34
CNR2 P34972 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
NPC1 O15118 3/20 0.32
LMNA P02545 3/20 0.32
MAPT P10636 3/20 0.32
RAB9A P51151 3/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
IDH1 O75874 1/20 0.32
HTT P42858 2/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566275 0.83 CNR2 (0.35) CNR1CNR2MEN1KMT2ALMNA
SCHEMBL3567403 0.82 CNR1 (0.34) CNR1UTS2RCNR2MEN1KMT2A
SCHEMBL3573299 0.79 CNR1 (0.41) CNR1UTS2RMAPTALDH1A1TSHR
SCHEMBL3557284 0.79 UTS2R (0.40) CNR1UTS2RMAPTALDH1A1TSHR
SCHEMBL3573284 0.78 CNR1 (0.36) CNR1UTS2RCNR2MEN1KMT2A
SCHEMBL8264048 0.73 F10 (0.44) CNR1UTS2RCNR2MEN1KMT2A
SCHEMBL3565837 0.72 CNR1 (0.39) CNR1SMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL3569301 0.72 CNR1 (0.39) CNR1KMT2ANPC1LMNAMAPT
SCHEMBL3569304 0.71 CNR1 (0.52) CNR1CNR2MEN1KMT2ASMN1; SMN2
SCHEMBL8265403 0.71 F10 (0.42) CNR1SMN1; SMN2NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 CNR1 1500/4885UTS2R 52/4885CNR2 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.